cytiva cell & gene therapy

Sarepta’s Elevidys makes advances towards expanded DMD label

Following an eventful couple of months with Elevidys (delandistrogene moxeparvovec-rokl), Sarepta Therapeutics has announced that the efficacy supplement for its…

Ascidian launches first-ever clinical study of RNA exon editor for vision loss

Ascidian Therapeutics’ lead RNA exon editor ACDN-01 is set to begin early-phase clinical trials for an inherited progressive vision loss,…

Vittoria’s CAR-T therapy secures clinical approval amid FDA scrutiny on sector

Vittoria Biotherapeutics will begin in-human studies of its lead chimeric antigen receptor (CAR)-T cell therapy candidate, VIPER-101, for relapsed or…

High risk, high reward – the future of CAR-T therapy in CLL

In 2010, two patients with end-stage refractory chronic lymphocytic leukaemia (CLL) were administered Novartis’ autologous anti-CD19 chimeric antigen receptor T-cell…